| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 101 | Nitroxyl progenitor compounds and methods of use | AU2005209843 | 2005-01-28 | AU2005209843B2 | 2012-02-16 | PAVLOS CHRISTOPHER M; TOSCANO JOHN P III; BOPPANA PREEYA KAPUR |
| Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions. | ||||||
| 102 | МАКРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ВИРУСНОЙ РЕПЛИКАЦИИ | EA200601467 | 2005-03-29 | EA012389B1 | 2009-10-30 | BLATT LAWRENCE M; WENGLOWSKY STEVEN M; ANDREWS STEVEN W; CONDROSKI KEVIN R; JIANG YUTONG; KENNEDY APRIL L; DOHERTY GEORGE A; JOSEY JOHN A; STENGEL PETER J; WOODARD BENJAMIN T; MADDURU MANCHESTER R |
| Настоящееизобретениераскрываетсоединенияобщихформул I-XIX, атакжекомпозиции, включающиефармацевтическиекомпозиции, содержащиесоединениепоизобретению. Представленноеизобретениетакжераскрываетспособылечения, включаяспособылеченияфлавивируснойинфекции, включаявируснуюинфекциюгепатитаС, испособылеченияфиброзапечени; способыобычновключаютвведениепациенту, которыйнуждаетсяв лечении, эффективногоколичествасоединенияиликомпозициипоизобретению. | ||||||
| 103 | VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES | CA2670341 | 2007-11-28 | CA2670341A1 | 2009-06-04 | ALVAREZ ANGEL; SUGAYA KIMINOBU |
| Disclosed herein are methods for increasing the overall vigor of a subjec t, and/or vigor of target tissues of a subject. Exemplified herein is the ut ilization of pyrimidine derivatives which act to stimulate stem cell prolife ration. In addition to increasing vigor, such stem cell proliferation agents (SCPA) may be used to enhance and/or improve the outcome of other therapies , and may be used in psychiatric applications. Increasing vigor in subjects is not necessarily targeted to the treatment of a disease, thus, the methods can include administration to clinically healthy animals. | ||||||
| 104 | UAA200608686 | 2005-01-28 | UA84189C2 | 2008-09-25 | ROSENQUIST ASA; THORSTENSSON FREDRIK; JOHANSSON PER-OLA; KVARNSTROEM INGEMAR; SAMUELSSON BERTIL; WALLBERG HANS | |
| Описаныпептидомиметическиесоединения, которыеингибируют NH3 протеазувирусагепатитаС (HCV). Соединенияимеютформулу, определениепеременныхкоторойпредставленов описании. СоединениявключаюткарбоциклическуюединицуР2 всоединениис новымисвязямис темичастямиингибитора, которыеболееотдаленыотноминальногоместарасщепленияестественногосубстрата, гдесвязиимеютобратнуюориентациюпептидныхсвязейнаотдаленнойсторонепоотношениюк тем, которыеявляютсяпроксимальнымик местурасщепления. | ||||||
| 105 | " INHIBIDORES MACROCÍCLICOS DEL VIRUS DE LA HEPATITIS C" | UY29705 | 2006-07-28 | UY29705A1 | 2007-05-31 | TAHRI ABDELLAH; GOWAN DAVID CRAIG MC; VREKEN WIN VAN DE; SURLERAUX DOMINIQUE LOUIS NEST; VENDEVILLE SANDRINE MARIE HELE; HU LILI; RABOISSON PIERRE JEAN-MARIE; KOCK HERMAN AUGUSTINUS DE; SIMMEN KENNETH ALAN |
| Inhibidores del VHC de fórmula (I) y los N-óxidos, sales y formas estereoquímicamente isoméricas de éstos, en los cuales R1, L, R2,R3, R4, n, p, arilo y Het son como fueron definidos en memoria descriptiva y reivindicaciones; composiciones farmacéuticas que contienen compuestos (I) y procesos para preparar los compuestos (I). También se proporcionan combinaciones biodisponibles de los inhibidores del VHC de fórmula (I) con ritonavir. | ||||||
| 106 | INHIBIDORES MACROCICLICOS DEL VIRUS DE LA HEPATITIS C | UY29704 | 2006-07-28 | UY29704A1 | 2007-05-31 | CLASSON BJORN OLOF; WALLBERG HANS KRISTIAN; SAHLBERG SVEN CRISTER; SAMUELSSON BENGT BERTIL; NILSSON KARL MAGNUS; ROSENQUIST ASA ANNICA KRISTINA; KAHNBERG PIA CECILIA; WAHLING HORST JURGEN; BELFRAGE ANNA KARIN GERTRUD; LINDSTROM MATS STEFAN; LINDQUIST KARIN CHARLOTTA; HU LILI; RABOISSON PIERRE JEAN-MARIE; KOCK HERMAN AUGUSTINUS DE; SIMMEN KENNETH ALAN |
| Compuestos de fórmula I: y sus N-óxidos, sales, y éstereoisómeros donde A es OR1, NHS(=O)pR2; donde; R1, R2; p; N; son tales como fueron definidos en la memoria descriptiva y reivindicaciones, -----denota un doble enlace opcional; L, Rz, Rq; Rr, R5, R6, son tales como fueron definidos en la memoria descriptiva y reivindicaciones tienen utilidad en el tratamiento o profilaxis de infecciones flavivirales tales como las originadas por el VHC. | ||||||
| 107 | НАНОПЛЁНОЧНЫЕ И МЕМБРАННЫЕ КОМПОЗИЦИИ | EA200401045 | 2003-02-07 | EA007470B1 | 2006-10-27 | KRIESEL JOSH; KARPISHIN TIMOTHY B; BIVIN DONALD B; MERRILL GRANT; EDELSTEIN MARTIN STUART; SMITH THOMAS H; WHITEFORD JEFFREY A; JONAS ROBERT THOMAS; MICKLATCHER MARK; JOSHI SERENA |
| Нанопленки, пригодныедляфильтрации, получаютизориентированныхамфифильныхмолекули ориентированныхмакроциклическихмодулей. Амфифильныечастицымогутбытьориентированынаграницеразделаилиповерхности. Нанопленкуможнополучитьосаждениемилиприсоединениемориентированногослояк подложке. Нанопленкутакжеможнополучить, соединяяориентированныемакроциклическиемодули, предоставляющиемембраны. | ||||||
| 108 | INHIBIDORES MACROCICLICOS DE LA SERINA PROTEASA NS3 DEL VIRUS DE LA HEPATITIS C | CO06029608 | 2006-03-24 | CO5680449A2 | 2006-09-29 | VENKATRAMAN SRIKANTH; NJOROGE F GEORGE; WU WANLI; GIRIJA VALLABHAN VIYYOOR M; MCKITTRICK BRIAN A; SU JING; VELASQUEZ FRANCISCO; PINTO PATRICK |
| 1.- Un compuesto que posee la estructura general que se muestra en la Fórmula 1: o sales, solvatos o ésteres aceptables para uso farmacéutico de dicho compuesto en el cual:(1) R1 es -C(O)R5 o -B(OR)2;(2) R5 es H, -OH, -OR8, -NR9R10, -C(O)OR8, -C(O)NR9R10, -CF3, -C2F5, C3F7, -CF2R6, -R6, -C(O)R7 o NR7SO2R8;(3) R7 es H, -OH, -OR8 o -CHR9R10;(4) R6, R8, R9 y R10 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquenilo, arilo, heteroalquilo, heteroarilo, cicloalquilo, arilalquilo, heteroarilalquilo, R14, -CH(R1AND#39)CH(R1AND#39)C(O)OR11, -[CH(R1AND#39)]pC(O)OR11, -[CH(R1AND#39)]pC(O)NR12R13,-[CH(R1AND#39)]pS(O2)R11,-[CH(R1AND#39)]pC(O)R11,-[CH(R1AND#39)]pS(O2)NR12R13, -CH(R1AND#39)C(O)N(H)CH(R2AND#39)(RAND#39),-CH(R1AND#39)CH(R1AND#39)C(O)NR12R13,-CH(R1AND#39)CH(R1AND#39)S(O2)R11, -CH(R1AND#39)CH(R1AND#39)S(O2)NR12R13,-CH(R1AND#39)CH(R1AND#39)C(O)R11,-[CH(R1AND#39)]pCH(OH)R11, -CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)OR11,-C(O)N(H)CH(R2AND#39)C(O)OR11, -C(O)N(H)CH(R2AND#39)C(O)R11,-CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)NR12R13,-CH(R1AND#39)C(O)N(H)CH(R2AND#39)RAND#39,-CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)N(H)CH(R3AND#39)C(O)OR11, -CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)CH(R3AND#39)NR12R13, -CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)N(H)CH(R3AND#39)C(O)NR12R13,-CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)N(H)CH(R3AND#39)C(O)N(H)CH (R4AND#39)C(O)OR11, -CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)N(H)CH(R3AND#39)C(O)N(H)CH(R4AND#39)C(O)NR12R13, -CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)N(H)CH(R3AND#39)C(O)N(H)CH(R4AND#39)C(O)N(H)-CH(R5AND#39)-C(O)OR11 y -CH(R1AND#39)C(O)N(H)CH(R2AND#39)C(O)N(H)CH(R3AND#39)C(O)N(H)CH (R4AND#39)C(O)N(H)-CH(R5AND#39)C(O)NR12R13; ... | ||||||
| 109 | COMPOSICIONES MODULARES MACROCICLICAS. | MXPA04007680 | 2003-02-07 | MXPA04007680A | 2006-01-30 | WHITEFORD JEFFERY A |
| Las composiciones modulares macrociclicas son producidas a partir de sintonas ciclicas. Las estructuras modulares macrociclicas son preparadas por esquemas de pasos o concertados los cuales acoplaron sintonas en un anillo cerrado. Las estructuras modulares macrociclicas pueden tener un poro de dimensiones nanometricas. | ||||||
| 110 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | CA2560897 | 2005-03-29 | CA2560897A1 | 2005-10-13 | JOSEY JOHN A; BLATT LAWRENCE M; JIANG YUTONG; WENGLOWSKY STEVEN M; STENGEL PETER J; WOODARD BENJAMIN T; CONDROSKI KEVIN R; ANDREWS STEVEN W; DOHERTY GEORGE A; KENNEDY APRIL L; MADDURU MACHENDER R |
| The embodiments provide macrocylic compounds, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | ||||||
| 111 | NITROXYL PROGENITOR COMPOUNDS AND METHODS OF USE | CA2554771 | 2005-01-28 | CA2554771A1 | 2005-08-18 | PAVLOS CHRISTOPHER M; BOPPANA PREEYA KAPUR; TOSCANO JOHN P III |
| Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions. | ||||||
| 112 | Macrocyclic inhibitors of hepatitis C virus NS3 serine protease | AU2004276281 | 2004-09-23 | AU2004276281A1 | 2005-04-07 | SU JING; WU WANLI; MCKITTRICK BRIAN; PINTO PATRICK A; VELAZQUEZ FRANCISCO; VENKATRAMAN SRIKANTH; GIRIJAVALLABHAN VIYYOOR M; NJOROGE F GEORGE |
| 113 | COMPOSICION DE BLANQUEADO QUE COMPRENDE UNA CLASE DE LIGANDO O COMPLEJO DEL MISMO UTIL COMO CATALIZADOR PARA BLANQUEAR CATALITICAMENTE SUSTRATOS CON OXIGENO ATMOSFERICO | ARP010105769 | 2001-12-12 | AR031908A1 | 2003-10-08 | BOERZEL HEIDI; COMBA PETER; HAGE RONALD; KERSCHER MARION; LIENKE JOACHIM; MERZ MICHAEL |
| La invencion se refiere al blanqueo catalítico de sustratos, especialmente telas de lavandería, con oxígeno atmosférico o aire. Se provee un método para blanquear un sustrato que comprende aplicar al sustrato, en un medio acuoso, un ligando específico de una clase seleccionada que forma un complejo con un metal de transicion, el complejo cataliza el blanqueo del sustrato por oxígeno atmosférico. También se provee una composicion blanqueadora acuosa sustancialmente carente de blanqueador de peroxígeno o sistema basado en peroxi o generador de blanqueo. | ||||||
| 114 | PROCESSES FOR SYNTHESIS OF CYCLIC AND LINEAR POLYAMINE CHELATORS CONTAINING N-MONOSUBTITUTED COORDINATING ARMS | AU2002254216 | 2002-03-14 | AU2002254216A1 | 2003-09-29 | WINCHELL HARRY S; CYJON ROSA L; KLEIN JOSEPH Y; SIMHON ELLIOT D; KLEIN OFER; ZAKLAD HAIM |
| 115 | LIGANDO Y COMPLEJO PARA BLANQUEAR CATALITICAMENTE UN SUBSTRATO. | MXPA03004887 | 2001-11-15 | MXPA03004887A | 2003-08-19 | BOERZEL HEIDI |
| 116 | IMPROVED PURIFICATION OF 4, 4'(5')-DI-T-BUTYLCYCLOHEXANO-18-CROWN-6 | CA2466934 | 2002-11-01 | CA2466934A1 | 2003-05-30 | BOND ANDREW H; HORWITZ E PHILIP; BARRANS RICHARD E |
| A purification method is disclosed for a predetermined water-insoluble extractant present in a liquid phase composition that additionally contains one or more additional extractants, synthesis reaction starting materials, a nd reaction byproducts dissolved as solutes in an organic diluent. An ion- containing compound is admixed with the composition to form an extractant/io n complex in the organic diluent phase that has an affinity for a new phase th at is greater than the affinity for the first-named phase. The predetermined extractant/ion complex is separated from the diluent by using the new phase affinity, and the extractant/ion complex is preferably although not necessarily recovered. The extractant/ion complex is separated into extracta nt and ion. The extractant is recovered. Exemplary extractants include polyethers, crown ethers, crown thioethers, calixarenes, polyamines, cryptands, porphyrins and the like. | ||||||
| 117 | Inhibitors of prenyl-protein transferase | AU2002254375 | 2002-03-26 | AU2002254375A1 | 2002-10-15 | SHAW ANTHONY W; DESOLMS S JANE |
| 118 | Ligand and complex for catalytically bleaching a substrate | AU3318702 | 2001-11-15 | AU3318702A | 2002-06-24 | BOERZEL HEIDI; COMBA PETER; HAGE RONALD; KERSCHER MARION; LIENKE JOACHIM; MERZ MICHAEL |
| 119 | Non-symmetric tripyrrannes in the synthesis of novel macrocycles | AU9058001 | 2001-08-28 | AU9058001A | 2002-03-13 | MODY TARAK; GALANTER JOSHUA |
| 120 | Matrix metalloproteinase inhibitors for inhibiting the release of TNF | NZ33355097 | 1997-06-20 | NZ333550A | 2000-07-28 | ALPEGIANI MARCO; ABRATE FRANCESCA; BISSOLINO PIERLUIGI; PALLADINO MASSIMILIANO; PERRONE ETTORE |
| These succinic amide derivatives are of formula (I), where: W is a -CO2H or -CONHOH group; R is H alkyl, phenyl or benzyl, R1 is H alkyl, (CH2)m-heterocyclyl, (CH2)m-cyclopropyl, (CH2)m-COOX, (CH2)m-SO2X, (CH2)m-SO3H, acyl, C(O)-X-heterocyclyl, C(O)-X-acyl or R and R1 may together with the N atom form a heterocyclic ring; R2 is alkyl or an organic residue, R3 is the characterising group of an a-aminoacid; and R4 is NHX where X is as defined ion the specification. The compounds are characterised as inhibitors of matrix metalloproteinases (MMPs) and of the release of tumor necrosis factor-alpha (TNF) from cells, and are therefore useful in the prevention, control and treatment of diseases in which MMPs or TNF are involved. | ||||||
QQ群二维码
意见反馈
意见反馈